Contracts › 75F40125C00098
75F40125C00098: Do Laboratory Prescribed and Ad Libitum Use Sessions Represent Real-World Ends Use
Awarded to Rochester Institute of Technology by Food and Drug Administration (FDA).
$4.5Mobligated
$4.5Mpotential value
24 September 2029current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40125C00098 |
|---|---|
| Awardee | Rochester Institute of Technology |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AJ11 General Science and Technology R&D Services; General Science and Technology; Basic Research |
| Place of performance | NY |
| Offers received | 1 |
| Period of performance | 30 September 2025 to 24 September 2029 |
| Potential end | 24 September 2029 |
| Estimated recompete solicitation | ~Q1 2029 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record